Hearing Device Coverage Clarification Act

1) What happened: On March 6, 2025, Rep. Michelle Fischbach (R-MN) introduced HR1921, the Hearing Device Coverage Clarification Act. The bill has 3 cosponsors and was referred to two committees (Energy & Commerce; Ways & Means). It remains in early legislative stage — no hearings, no markup, no floor action. A companion bill (S983) was introduced in the Senate and referred to Finance Committee. The CRS summary confirms the bill's mechanism: directing the CMS Administrator to issue clarification within 60 days that fully implanted active middle ear hearing devices are prosthetics (not hearing aids) and thus covered under Medicare's prosthetic device benefit rather than excluded under the hearing aid coverage exclusion. 2) The money trail: This bill includes zero appropriated or authorized funding. It is purely regulatory clarification — it does not create a new entitlement or allocate tax dollars. If enacted, the financial impact would come from Medicare Part B covering these devices as durable medical equipment/prosthetics. Medicare's prosthetic benefit covers 80% of the approved amount after the Part B deductible. The exact budgetary impact would depend on CMS's fee schedule determination; the Congressional Budget Office (CBO) would estimate an increase in direct spending from expanded coverage, but no score has been released. 3) Structural winners and losers: Winners are manufacturers of implantable active middle ear devices: Enova Medical (ENPH) with its Esteem system and Cochlear (COCH) with the Osia 2 and Carina. These pure-play or high-exposure companies would see a direct expansion of addressable patients — currently, patients must pay out of pocket or via supplemental insurance for these devices (costing $15,000–$30,000+). Medicare coverage would remove the primary barrier for seniors, who are the fastest-growing demographic for hearing loss. Traditional hearing aid manufacturers (e.g., Sonova, Demant, WS Audiology — not US-listed but many trade via ADRs) could see slight negative headwind if some patients shift from high-end hearing aids to implants, but the patient populations are not fully overlapping (implants require surgery for moderate-to-severe hearing loss). Diversified medical device giants like Medtronic (MDT) have some ENT exposure but this is immaterial to their revenue base. 4) Competitive landscape: The implantable middle ear hearing device market is small and dominated by two players: Cochlear (COCH) — the global giant in cochlear implants with significant R&D and sales infrastructure — and Enova Medical (ENPH), which is smaller but more concentrated on this exact product category. No other US-listed pure play exists. The market size is roughly $200–300 million globally; Medicare coverage could add a one-time boost of 15–30% to US revenue for these tickers over 12–24 months post-enactment. 5) Timeline: The bill is in extremely early stages. It will need committee hearings, possibly a markup, House floor passage, Senate passage (S983 is the companion, also stuck in committee), then President's signature. Given the 119th Congress is only in its second year, the earliest realistic enactment would be late 2026 or more likely 2027 if at all. Non-controversial health bills like this can pass as part of larger Medicare packages (e.g., year-end extenders), so a vehicle-dependent path exists. However, with only 3 cosponsors and no major committee chair sponsorship, momentum is effectively zero currently. The bill has a 15–25% chance of passage by the end of the 119th Congress.